Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $481.56M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.12M
Average 0.17M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$71.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +115.36% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -3.81% |
Zymeworks Inc. NASDAQ:ZYME | $1.83B | $26.24 | Not rated | -16.6 | +12.40% |
Bicycle Therapeutics plc NASDAQ:BCYC | $236.22M | $3.37 | Not rated | -1.3 | -50.54% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | $1.34 | Not rated | -1.2 | -66.25% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | $1.38 | Not rated | -3.0 | -26.11% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $143.81M | $1.04 | Not rated | -0.9 | -38.34% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +33.12% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | $0.77 | Not rated | -5.5 | -87.69% |
Actinium Pharmaceuticals, Inc. AMEX:ATNM | $51.56M | $1.64 | Not rated | 4.4 | +14.69% |
Continue the stock analysis
Jump to another research area for this company.